TriSalus Life Sciences, Inc. TLSI 深 滬
等待開盤 09-24 09:30:00 美东时间
5.185
+0.255
+5.17%
華盛通- 最 高5.83
- 今 開5.78
- 成交量 230.04万股
- 最 低 5.1001
- 昨 收 4.93
- 總市值 31.93万
- 52周最高 7.95
- 市盈率 靜 --
- 換手率 3735.93%
- 52周最低 2.20
- 委 比 11.11%
- 總股本 6.16万
- 歷史最高 16.24
- 量 比 4.07
- 振 幅 14.81%
- 歷史最低 2.20
- 每 手 1
- 風險率 0.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
The U.S. Food and Drug Administration (FDA) on Wednesday granted 510(k) clearance for TriSalus Life Sciences Inc.’s (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio. TLSI Stock Slides After FDA Clearance For TriNav Advance TriSalus said the FDA...
今天 01:26
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Shares of Worthington Enterprises, Inc (NYSE:WOR) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results. Worthington reported quarterly earnings of 82 cents per share, which beat the analyst consensus estimate of 75 cents per share. The co...
09-23 16:27
美股夜盘 | TriSalus Life Sciences, Inc.暴升16.63%，最新股价5.75美元
TriSalus Life Sciences, Inc.暴升16.63%，报5.75美元
09-23 08:01
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
HC Wainwright & Co. Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $11
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $11.
09-09 18:11
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
TriSalus Life Sciences Lowers FY2026 Sales Guidance from $60.000M-$62.000M to $54.000M-$57.000M vs $59.960M Est
TriSalus Life Sciences (NASDAQ:TLSI) lowers FY2026 sales outlook from $60.000 million-$62.000 million to $54.000 million-$57.000 million vs $59.960 million estimate.
05-13 04:03
TriSalus Life Sciences Q1 EPS $0.03 Beats $(0.16) Estimate, Sales $8.899M Miss $10.440M Estimate
TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.16) by 118.75 percent. This is a 107.69 percent increase over losses of $(0.39) per
05-13 04:02
TriSalus Life Sciences Announces Publication Of Study On Pressure-Enabled Drug Delivery Used In Trans Arterial Chemoembolization And Radioembolization
The study, titled "Clinical Outcomes of Pressure-Enabled Drug Delivery (PEDD) for Trans-Arterial Chemoembolization (TACE) and Radioembolization (TARE)," was published online on April 9, 2026 in the Journal of Comparative
05-12 20:17
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
